



ARCXIS BIOTECHNOLOGIES® ANNOUNCES RELEASE OF FIRST COMMERCIAL PRODUCT FOR MOLECULAR ANALYSIS

Arcxis Biotechnologies® Announces the Launch of ArcPure™ Viral DNA and Viral RNA Sample Preparation Kits for Life Science and Clinical Laboratories

October 5, 2009

Arcxis Biotechnologies is pleased to announce the availability of their first commercial product line: the ArcPure™ line of nucleic acid isolation and purification kits. These sample preparation kits are optimized to extract and purify viral DNA and RNA from plasma and whole blood. The ArcPure kits are designed to increase downstream assay sensitivity, a critical component of the molecular analytical process. In addition, the product line offers an exceptionally cost effective approach to efficient and expeditious extraction, purification and concentration of nucleic acids using standard laboratory equipment.

The ArcPure line leverages components of the company's patented automated molecular system technologies, currently under development. As such, the kits offer technologists and investigators cutting edge performance in a familiar format, at a significantly lower cost than standard commercially available products. "We were inspired to develop the ArcPure spincolumn technology based on the superior performance of Xisyl™, our pre-market automated sample preparation system", commented Arcxis Biotechnologies CEO, Chris Meda. "We are proud of the superior quality of the kits and pleased to offer a robust, cost-effective option to researchers and clinical laboratorians alike."

The ArcPure Sample Preparation kits will initially be available for purchase via the Arcxis ecommerce site, beginning October first.

About Kaiser Permanente Ventures:

Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, makes investments in medical devices, healthcare services and information technology companies. Kaiser Permanente Ventures is dedicated to partnering with entrepreneurial companies to build innovative and enduring businesses that advance the quality and affordability of health care. Since its inception in 1997, Kaiser Permanente Ventures has invested in more than 25 venture-capital backed companies at all stages of development, and contributed organizational expertise, time and resources to the success of these companies. For additional information please visit www.kpventures.com.